EUCTR2020-000769-18-Outside-EU/EEAActive, not recruitingPhase 1
A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV001) in previously treated pediatric patients <12 years of age with severe hemophilia A - XTEND-Kids
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Bioverativ Therapeutics Inc.
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Male
Inclusion Criteria
- •- Participant must be younger than 12 years of age, at the time of signing the informed consent
- •- Severe hemophilia A defined as <1 IU/dL (<1%) endogenous FVIII as documented either by central laboratory testing at Screening or in historical medical records from a clinical laboratory demonstrating <1% FVIII coagulant activity (FVIII:C) or a documented genotype known to produce severe hemophilia A.
- •- Previous treatment for hemophilia A (prophylaxis or on-demand) with any recombinant and/or plasma-derived FVIII, or cryoprecipitate for at least 150 EDs for patients aged 6-11 years and above 50 EDs for patients aged <6 years
- •- Weight above or equal to 10 kg.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 70
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- History of hypersensitivity or anaphylaxis associated with any FVIII product.
- •- History of a positive inhibitor (to FVIII) test defined as =0.6 BU/mL, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors will not exclude the participant.
- •- Positive inhibitor test result, defined as =0.6 BU/mL at Screening.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia AHemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2020-000769-18-BEBioverativ Therapeutics Inc.70
Not yet recruiting
Phase 3
A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV001) in previously treated pediatric patients <12 years of age with severe hemophilia A10064477hemophilia A10005330NL-OMON49869Genzyme Europe BV3
Active, not recruiting
Phase 1
Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-000769-18-ITBIOVERATIV THERAPEUTICS INC70
Active, not recruiting
Phase 1
Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-000769-18-HUBioverativ Therapeutics Inc.70
Active, not recruiting
Phase 1
Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-000769-18-IEBioverativ Therapeutics Inc.70